Stock comparison
Alnylam Pharmaceuticals
LeMaitre Vascular
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
ALNY
Alnylam Pharmaceuticals
Market cap
$39.71B
Sector
Healthcare
LMAT
LeMaitre Vascular
Market cap
$2.23B
Sector
Healthcare
Overall winner
Alnylam Pharmaceuticals ALNY
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | ALNY | LMAT | Winner |
|---|---|---|---|
| Warren Buffett | 58C | 77B | LMAT |
| Benjamin Graham | 80D | 89A | LMAT |
| Philip Fisher | 79B | 81C | LMAT |
| Peter Lynch | 81A | 67B | ALNY |
| Joel Greenblatt | 63C | 56D | ALNY |
| Charlie Munger | 75D | 68D | ALNY |
| Terry Smith | 75B | 69D | ALNY |
Side-by-side metrics
| Metric | ALNY | LMAT |
|---|---|---|
| Market cap | $39.71B | $2.23B |
| P/E (TTM) | 66.1x | 37.1x |
| EV/EBIT | 75.5x | 36.6x |
| ROIC (TTM) | 19.66% | 9.43% |
| Gross margin | 80.89% | 72.39% |
| Net margin | 13.46% | 24.35% |
| Revenue CAGR 5y | 44.82% | 12.75% |
| EPS CAGR 5y | 38.42% | 19.04% |
| Debt / Equity | 1.2x | 0.5x |
| Dividend yield | 0.0% | 0.84% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
ALNY leads on
- Market cap$39.71Bvs $2.23B+94%
- Revenue CAGR 5y44.82%vs 12.75%+72%
- ROIC (TTM)19.66%vs 9.43%+52%
- EPS CAGR 5y38.42%vs 19.04%+50%
LMAT leads on
- Dividend yield0.84%vs 0.0%+100%
- Debt / Equity0.5xvs 1.2x+61%
- EV/EBIT36.6xvs 75.5x+52%
- Net margin24.35%vs 13.46%+45%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.